Bio Business

» cancer, biotech and biobusiness

Most Recent

image: Flux and Uncertainty in the CRISPR Patent Landscape

Flux and Uncertainty in the CRISPR Patent Landscape

By | October 1, 2017

The battle for the control of the intellectual property surrounding CRISPR-Cas9 is as storied and nuanced as the technology itself.

0 Comments

image: Accessing Drugs for Medical Aid-in-Dying

Accessing Drugs for Medical Aid-in-Dying

By | August 17, 2017

A fraught market for the barbiturates prescribed to terminally ill patients who choose to end their lives has physicians turning to options outside big pharma.

0 Comments

image: Learning from Iceland’s Model for Genetic Research

Learning from Iceland’s Model for Genetic Research

By | June 1, 2017

The Scandinavian island’s unique combination of genetic homogeneity, genealogical tradition, and high participation in research make it a prime location for discovery and validation of drug targets.

1 Comment

image: Making CAR T-Cell Therapy Safer

Making CAR T-Cell Therapy Safer

By | April 1, 2017

Following a spate of patient deaths in clinical trials testing modified T cells for the treatment of cancer, researchers work to reduce the treatment’s toxicity without sacrificing efficacy.

0 Comments

image: Oligonucleotide Therapeutics Near Approval

Oligonucleotide Therapeutics Near Approval

By | December 1, 2016

Successful late-stage clinical trials could mark the maturation of a new drug development platform, but the path to commercialization is not without hurdles.

0 Comments

image: The Growth of Iowa Biotech

The Growth of Iowa Biotech

By | August 1, 2016

The state’s industry draws inspiration from medicine as well as agriculture.

1 Comment

image: Banking on Blood Tests

Banking on Blood Tests

By | April 1, 2016

How close are liquid biopsies to replacing current diagnostics?

1 Comment

image: The Sounds of Silence

The Sounds of Silence

By | September 1, 2015

Science-based tinnitus therapeutics are finally coming into their own.

4 Comments

image: The CAR T-Cell Race

The CAR T-Cell Race

By | April 1, 2015

Tumor-targeting T-cell therapies are generating remarkable remissions in hard-to-beat cancers—and attracting millions of dollars of investment along the way.

2 Comments

image: Lazarus Drugs

Lazarus Drugs

By | February 1, 2015

While some drugs sail through development, others suffer setbacks, including FDA rejections, before reaching the market.  

1 Comment

Popular Now

  1. GM Mosquitoes Closer to Release in U.S.
  2. Judge Recommends Ruling to Block Internet Access to Sci-Hub
  3. Opinion: Microbiology Needs More Math
  4. Do Pathogens Gain Virulence as Hosts Become More Resistant?
RayBiotech